

Article

A Physically Active Status Affects the Circulating Profile of Cancer-Associated miRNAs

Martina Faraldi ¹, Laura Gerosa ^{2,*}, Marta Gomasca ¹, Veronica Sansoni ¹, Silvia Perego ¹,
Ewa Ziemann ³, Giuseppe Banfi ^{1,4} and Giovanni Lombardi ^{1,3}

¹ IRCCS Istituto Ortopedico Galeazzi, Laboratory of Experimental Biochemistry & Molecular Biology, 20161 Milano, Italy; martina.faraldi@grupposandonato.it (M.F.); marta.gomasca@grupposandonato.it (M.G.); veronica.sansoni@grupposandonato.it (V.S.); silvia.perego@grupposandonato.it (S.P.); banfi.giuseppe@univr.it (G.B.); giovanni.lombardi@grupposandonato.it (G.L.)

² Gruppo San Donato Foundation, 20122 Milano, Italy

³ Department of Athletics, Strength and Conditioning, Poznań University of Physical Education, 61-871 Poznań, Poland; ziemann@awf.poznan.pl

⁴ Vita-Salute San Raffaele University, 20132 Milano, Italy

* Correspondence: laura.gerosa@grupposandonato.it; Tel.: +39-02166214068

Citation: Faraldi, M.; Gerosa, L.; Gomasca, M.; Sansoni, V.; Perego, S.; Ziemann, E.; Banfi, G.; Lombardi, G. A Physically Active Status Affects the Circulating Profile of Cancer-Associated miRNAs. *Diagnostics* **2021**, *11*, 820. <https://doi.org/10.3390/diagnostics11050820>

Academic Editor: Anastasia Malek

Received: 24 March 2021

Accepted: 29 April 2021

Published: 30 April 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).

Supplementary Table S3. List of the miRNAs and miRNA signatures associated with diagnosis in Prostate Cancer from literature. Only miRNAs with significant clinical relevance ($AUC \geq 0.7$), and signature with at least one modulated miRNA from our experimental setting were considered.

| Cancer | Sample | miRNAs | miRNA signatures | Regulation | AUC | Reference |
|--------|--------|------------|------------------|--------------|-------------------|----------------------|
| PC | Serum | miR-106a | | miR-106a ↑ | miR-106a: 0.928 | [1] |
| | | miR-223 | | miR-223 ↓ | miR-223: 0.876 | |
| | | miR-24 | | miR-24 ↓ | miR-24: 0.778 | |
| | | miR-874 | | miR-874 ↑ | miR-874: 0.845 | |
| | | miR-93 | | miR-93 ↑ | miR-93: 0.907 | |
| PC | Serum | let-7b | | let-7b ↓ | let-7b: 0.848 | [2] |
| | | miR-141 | | miR-141 ↑ | miR-141: 0.929 | |
| | | miR-205 | | miR-205 ↓ | miR-205: 0.914 | |
| | | miR-484 | | miR-484 ↓ | miR-484: 0.786 | |
| | | miR-106b | | miR-106b ↑ | miR-106b: 0.750 | |
| PC | Serum | miR-141-3p | | miR-141-3p ↑ | miR-141-3p: 0.831 | [3] |
| | | miR-21 | | miR-21 ↑ | miR-21: 0.856 | |
| PC | Serum | miR-375 | | miR-375 ↑ | miR-375: 0.906 | [4] |
| PC | Plasma | miR-375 | | miR-375 ↑ | miR-375: 0.757 | |
| PC | Plasma | miR-145-5p | | miR-145-5p ↓ | miR-145-5p: 0.900 | [5] |
| PC | Plasma | miR-152-3p | | miR-152-3p ↑ | miR-326: 0.910 | [6] |
| PC | Plasma | miR-326 | | miR-326 ↑ | miR-152-3p: 0.820 | |
| PC | Plasma | miR-141 | | miR-141 ↑ | miR-141: 0.800 | [7] |
| PC | Plasma | miR-375 | | miR-375 ↓ | miR-375: 0.711 | [8] |
| PC | Plasma | miR-21 | miR-21 | miR-21 ↑ | miR-21: 0.880 | [9] |
| | | miR-221 | miR-221 | miR-221 ↑ | miR-221: 0.830 | |
| PC | Plasma | | | | signature: 0.897 | [10] |
| | | let-7c | | let-7c ↓ | let-7c: 0.775 | |
| | | let-7e | | let-7e ↓ | let-7e: 0.804 | |
| | | miR-30c | | miR-30c ↓ | miR-30c: 0.818 | |

PC: prostate cancer; AUC: area under the ROC curve.

References

- Moltzahn, F.; Olshen, A.B.; Baehner, L.; Peek, A.; Fong, L.; Stoppler, H.; Simko, J.; Hilton, J.F.; Carroll, P.; Billeloch, R. Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients. *Cancer research* **2011**, *71*, 550–560, doi:10.1158/0008-5472.CAN-10-1229.
- Guo, X.; Han, T.; Hu, P.; Guo, X.; Zhu, C.; Wang, Y.; Chang, S. Five microRNAs in serum as potential biomarkers for prostate cancer risk assessment and therapeutic intervention. *International urology and nephrology* **2018**, *50*, 2193–2200, doi:10.1007/s11255-018-2009-4.
- Porzycki, P.; Ciszakowicz, E.; Semik, M.; Tyrka, M. Combination of three miRNA (miR-141, miR-21, and miR-375) as potential diagnostic tool for prostate cancer recognition. *International urology and nephrology* **2018**, *50*, 1619–1626, doi:10.1007/s11255-018-1938-2.
- Wach, S.; Al-Janabi, O.; Weigelt, K.; Fischer, K.; Greither, T.; Marcou, M.; Theil, G.; Nolte, E.; Holzhausen, H.J.; Stohr, R.; et al. The combined serum levels of miR-375 and urokinase plasminogen activator receptor are suggested as diagnostic and prognostic biomarkers in prostate cancer. *International journal of cancer* **2015**, *137*, 1406–1416, doi:10.1002/ijc.29505.
- Chen, Z.; Zhen, M.; Zhou, J. LncRNA BRE-AS1 interacts with miR-145-5p to regulate cancer cell proliferation and apoptosis in prostate carcinoma and has early diagnostic values. *Bioscience reports* **2019**, *39*, doi:10.1042/BSR20182097.
- Matin, F.; Jeet, V.; Moya, L.; Selth, L.A.; Chambers, S.; Australian Prostate Cancer, B.; Clements, J.A.; Batra, J. A Plasma Biomarker Panel of Four MicroRNAs for the Diagnosis of Prostate Cancer. *Scientific reports* **2018**, *8*, 6653, doi:10.1038/s41598-018-24424-w.
- Osipov, I.D.; Zaporozhchenko, I.A.; Bondar, A.A.; Zaripov, M.M.; Voytsitskiy, V.E.; Vlassov, V.V.; Laktionov, P.P.; Morozkin, E.S. Cell-Free miRNA-141 and miRNA-205 as Prostate Cancer Biomarkers. *Advances in experimental medicine and biology* **2016**, *924*, 9–12, doi:10.1007/978-3-319-42044-8_2.
- Kachakova, D.; Mitkova, A.; Popov, E.; Popov, I.; Vlahova, A.; Dikov, T.; Christova, S.; Mitev, V.; Slavov, C.; Kaneva, R. Combinations of serum prostate-specific antigen and plasma expression levels of let-7c, miR-30c, miR-141, and miR-375 as potential better diagnostic biomarkers for prostate cancer. *DNA and cell biology* **2015**, *34*, 189–200, doi:10.1089/dna.2014.2663.
- Yaman Agaoglu, F.; Kovancilar, M.; Dizdar, Y.; Darendeliler, E.; Holdenrieder, S.; Dalay, N.; Gezer, U. Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer. *Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine* **2011**, *32*, 583–588, doi:10.1007/s13277-011-0154-9.
- Chen, Z.H.; Zhang, G.L.; Li, H.R.; Luo, J.D.; Li, Z.X.; Chen, G.M.; Yang, J. A panel of five circulating microRNAs as potential biomarkers for prostate cancer. *The Prostate* **2012**, *72*, 1443–1452, doi:10.1002/pros.22495.